← Back to Screener
RenovoRx, Inc. Common Stock (RNXT)
Price$1.00
Favorite Metrics
Price vs S&P 500 (26W)-18.66%
Price vs S&P 500 (4W)-9.49%
Market Capitalization$45.05M
All Metrics
Book Value / Share (Quarterly)$0.15
P/TBV (Annual)1.17x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.30
Price vs S&P 500 (YTD)14.90%
Gross Margin (TTM)70.88%
Net Profit Margin (TTM)-994.48%
EPS (TTM)$-0.32
10-Day Avg Trading Volume0.28M
EPS Excl Extra (TTM)$-0.32
EPS (Annual)$-0.32
ROI (Annual)-205.98%
Gross Margin (Annual)70.88%
Cash / Share (Quarterly)$0.19
Revenue Growth QoQ (YoY)453.49%
ROA (Last FY)-137.96%
EBITD / Share (TTM)$-0.33
ROE (5Y Avg)-173.15%
Operating Margin (TTM)-1113.98%
Cash Flow / Share (Annual)$-0.30
P/B Ratio8.31x
P/B Ratio (Quarterly)5.68x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)33.86x
Net Interest Coverage (TTM)-6.61x
ROA (TTM)-91.25%
EPS Incl Extra (Annual)$-0.32
Current Ratio (Annual)4.02x
Quick Ratio (Quarterly)3.76x
3-Month Avg Trading Volume0.31M
52-Week Price Return-2.91%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.00
P/S Ratio (Annual)40.12x
Asset Turnover (Annual)0.14x
52-Week High$1.45
EPS Excl Extra (Annual)$-0.32
26-Week Price Return-9.91%
Quick Ratio (Annual)3.76x
13-Week Price Return-5.66%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.02x
Enterprise Value$38.029
Asset Turnover (TTM)0.09x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-994.48%
Cash / Share (Annual)$0.19
3-Month Return Std Dev67.75%
Net Income / Employee (TTM)$-1
ROE (Last FY)-205.98%
Net Interest Coverage (Annual)-3.73x
EPS Basic Excl Extra (Annual)$-0.32
Receivables Turnover (TTM)12.34x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.32
ROI (TTM)-119.77%
P/S Ratio (TTM)40.12x
Revenue / Share (Annual)$0.03
Tangible BV / Share (Annual)$0.68
Price vs S&P 500 (52W)-38.01%
Year-to-Date Return19.03%
5-Day Price Return-1.96%
EPS Normalized (Annual)$-0.32
ROA (5Y Avg)-223.86%
Net Profit Margin (Annual)-994.48%
Month-to-Date Return-0.99%
EBITD / Share (Annual)$-0.33
Operating Margin (Annual)-1113.98%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-173.15%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.32
P/TBV (Quarterly)1205.88x
P/B Ratio (Annual)5.68x
Pretax Margin (TTM)-994.48%
Book Value / Share (Annual)$0.15
Price vs S&P 500 (13W)-8.53%
Beta1.07x
Revenue / Share (TTM)$0.03
ROE (TTM)-119.77%
52-Week Low$0.70
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.10
4.09
4.10
4.10
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
RNXTRenovoRx, Inc. Common Stock | 40.12x | — | 70.88% | — | $1.00 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
RenovoRx is a clinical-stage biopharmaceutical company developing targeted combination cancer therapies. Its proprietary Trans-Arterial Micro-Perfusion platform delivers therapeutics directly to tumors to potentially enhance efficacy while reducing toxicities compared to systemic intravenous therapy.